(Version française à venir...)
This new team will focus on discovering and developing predictive and prognostic biomarkers for personalized management in GI oncology. The team includes full time researchers working on basic and translational aspects, as well as clinicians and aims at developing integrative and clinically-relevant GI cancer research. Our project leans on a variety of interdisciplinary skills in basic research of signaling pathways, molecular biology and pathology, tumor microenvironment, pharmacokinetics, imaging biomarkers, biostatistics and clinical research. Research works will involve basic and applied researchers as well as clinicians to develop innovative translational GI cancer research programs. Specifically, we are interested in the analysis of circulating cell free DNA and miRNA, protein dimerization profiles, wnt/β-Catenin oncogenic signaling pathways, pharmacokinetic and pharmacodynamic models applied to cytotoxic/targeted agents and their metabolites, novel imaging predictors. An additional asset will be the integration of biostatistics methodological research for biomarkers evaluation. Special emphasis will be directed towards the expression of new molecular and genetic markers on human tumor/tissue samples.
In line with the colorectal cancer research program conducted through the Integrated Cancer Research Site “SIRIC Montpellier Cancer”, our plan is to establish new ties between basic research and clinical needs to achieve significant and practice-changing advances in GI cancer research.
Prévostel C, Blache P. The dose-dependent effect of SOX9 and its incidence in colorectal cancer. Eur J Cancer. 2017 Oct 5;86:150-157.
Barbieri A, Peyhardi J, Conroy T, Gourgou S, Lavergne C, Mollevi C. Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials. BMC Med Res Methodol. 2017 Sep 26;17(1):148. doi: 10.1186/s12874-017-0410-9.
Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330.
Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, Zghaib Z, Khier S, Deleuze-Masquefa C, Gattacceca F. Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. PLoS One. 2017 Aug 10;12(8):e0182022. doi: 10.1371/ journal.pone.0182022. eCollection 2017.
Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017 Aug 19;84:239-249. doi: 10.1016/j.ejca.2017.07.038. [Epub ahead of print]